CMS proposes deeper 340B drug payment cuts for hospitals, reshaping outpatient cancer economics, consolidation incentives, and patient cost-sharing. The Centers for Medicare & Medicaid Services (CMS) ...
A Legislative History of the 340B Drug Pricing Program, a new research paper published in The Milbank Quarterly, is the ...
CMS targets 340B site-neutral pay in its 2027 outpatient rule, cutting drug payments and expanding site-neutral rates to imaging services.
Between the megabill’s July 2025 enactment and March 2026 (the last month with data on all states): These participation declines began before some of the major changes from H.R. 1 were fully in effect ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results